昂利康：与亚飞生物、亲合力签署授权许可协议

Core Viewpoint - The announcement highlights a strategic collaboration between the company, Aifei Bio, and Qinhuli, focusing on the licensing of the IMD-1005 drug molecule, granting the company exclusive rights for research, production, and commercialization in specified regions [1] Group 1 - The company signed a licensing agreement with Aifei Bio and Qinhuli for the IMD-1005 drug molecule [1] - The company will pay a total of 150 million RMB as an initial payment to Aifei Bio and Qinhuli [1] - The company may pay up to 620 million RMB in milestone payments related to research and sales to Qinhuli [1] Group 2 - The company is required to pay a sales share of 12.8% to Qinhuli during the sales revenue sharing period [1]